LRRC3B: A Potential Drug Target and Biomarker for Diseases (G116135)

Target Name: LRRC3B

NCBI ID: G116135

LRRC3B

LRRC3B: A Potential Drug Target and Biomarker for Diseases

LRRC3B, also known as Leucine rich repeat containing 3B, is a protein that is expressed in various tissues throughout the body. It is a member of the leucine rich repeat (LRR) family, which is a common structural motif found in proteins that plays a crucial role in various cellular processes. LRRC3B has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The LRRC3B protein is composed of 21 amino acid residues and has a calculated molecular mass of 31.1 kDa. It is expressed in various tissues, including muscle, heart, brain, and lymphoid organs. LRRC3B is localized to the endoplasmic reticulum (ER) and can be detected in the cytoplasm using various techniques, such as immunofluorescence and Western blotting.

LRRC3B has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and stress response. It is a component of several signaling pathways, including the TOR signaling pathway, the PI3K/Akt signaling pathway, and the NF-kappa-B signaling pathway. LRRC3B has also been shown to interact with several protein partners, including 尾-catenin, N-cadherin, and PDGF-尾1.

In addition to its role in cellular signaling, LRRC3B has also been shown to be involved in the development and progression of various diseases. For example, LRRC3B has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, LRRC3B has been shown to be involved in the development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

LRRC3B has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that LRRC3B can be used as a biomarker for cancer, by detecting its expression and stability in cancer tissues and fluids. Additionally, LRRC3B has been shown to be involved in the development of neurodegenerative diseases, by regulating the production of beta-amyloid in neurofibrillary tangles. It has also been shown to be involved in the development of autoimmune disorders, by regulating the production of autoantibodies in the immune system.

In conclusion, LRRC3B is a protein that has been shown to play a role in various cellular processes and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of LRRC3B in cellular signaling and disease development.

Protein Name: Leucine Rich Repeat Containing 3B

The "LRRC3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets